Home › Compare › RIDYF vs ABBV
RIDYF yields 3.79% · ABBV yields 3.06%● Live data
📍 RIDYF pulled ahead of the other in Year 2
Combined, RIDYF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RIDYF + ABBV for your $10,000?
Ridley Corporation Limited, together with its subsidiaries, provides animal nutrition solutions in Australia. It operates in two segments, Packaged Feeds and Ingredients, and Bulk Stockfeeds. The company offers packaged products and supplements, such as bagged poultry, dairy, dog, horse, and lifestyle animal feeds, as well as block and loose lick supplements; aquafeed, which includes extruded and steam pelleted products for various fin fish and prawns; and rendered poultry, red meat, and fish products for the pet food, stockfeed, and aquaculture sectors. It also provides monogastric and ruminant feeds, such as pellets, meals, concentrates, and premixes for poultry, pigs, dairy cattle, beef cattle, and sheep. In addition, the company provides nutrition solutions to various food producers in the dairy, poultry, pig, aquaculture, sheep, and beef industries; laboratory animals in the research sector; and equine, canine, and home layer markets in retail sector. The company offers its products primarily under the Barastoc, Rumevite, Cobber, Primo, and Food for Dogs brands. It also exports its products. Ridley Corporation Limited was incorporated in 1987 and is headquartered in Melbourne, Australia.
Full RIDYF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.